Trials / Withdrawn
WithdrawnNCT01454687
Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The term epidermolysis bullosa (EB) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "Revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. Some EB patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. In the revertant areas, the proteins function normally, like non-EB skin. In this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Grafting of Autologous Cultured Revertant Keratinocytes | Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-04-01
- First posted
- 2011-10-19
- Last updated
- 2014-04-11
Source: ClinicalTrials.gov record NCT01454687. Inclusion in this directory is not an endorsement.